Evaluate Vantage Homepage
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Company Events
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Viridian aims to prove itself in thyroid eye
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.
Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
Interviews
Scribe signs another big pharma deal
Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Iteos – and GSK – keep the faith
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?